ArticleBMC medical imaging2025
CT-based deep learning radiomics model for predicting proliferative hepatocellular carcinoma: application in transarterial chemoembolization and radiofrequency ablation.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Selection of proper artificial intelligence techniques developed for CT scan image analysis of liver cancer using fuzzy AHP-TOPSIS.BMC medical imaging · 2026Article
- Spectral CT quantitative parameters for predicting complete ablation after radiofrequency ablation in liver tumors: a retrospective study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesProliferative hepatocellular carcinoma (HCC) is an aggressive tumor with varying prognosis depending on the different disease stages and subsequent treatment. This study aims to develop and validate a deep learning radiomics (DLR) model based on contrast-enhanced CT to predict proliferative HCC and to implement risk prediction in patients treated with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA). MATERIALS AND
methods312 patients (mean age, 58 years ± 10 [SD]; 261 men and 51 women) with HCC undergoing surgery at two medical centers were included, who were divided into a training set (n = 182), an internal test set (n = 46) and an external test set (n = 84). DLR features were extracted from preoperative contrast-enhanced CT images. Multiple machine learning algorithms were used to develop and validate proliferative HCC prediction models in training and test sets. Subsequently, patients from two independent new sets (RFA and TACE sets) were divided into high- and low-risk groups using the DLR score generated by the optimal model. The risk prediction value of DLR scores in recurrence-free survival (RFS) and time to progression (TTP) was examined separately in RFA and TACE sets.
resultsThe DLR proliferative HCC prediction model demonstrated excellent predictive performance with an AUC of 0.906 (95% CI 0.861–0.952) in the training set, 0.901 (95% CI 0.779–1.000) in the internal test set and 0.837 (95% CI 0.746–0.928) in the external test set. The DLR score effectively enables risk prediction for patients in RFA and TACE sets. For the RFA set, the low-risk group had significantly longer RFS compared to the high-risk group (P = 0.037). Similarly, the low-risk group showed a longer TTP than the high-risk group for the TACE set (P = 0.034).
conclusionsThe DLR-based contrast-enhanced CT model enables non-invasive prediction of proliferative HCC. Furthermore, the DLR risk prediction helps identify high-risk patients undergoing RFA or TACE, providing prognostic insights for personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.